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Supplement Aims and Scope
The supplement aims to provide readers with an exploration
of recent advances in research on and treatment of heart
failure. This includes but is not limited to the following
topics:
Pathophysiology
Evaluation
Management
Diagnosis
Prognosis
Treatment
Screening
Prevention
Epidemiology
Risk factor modification

H

eart function fails when the organ is unable to pump
blood at a rate proportional to the body’s need for
oxygen or when this function leads to elevated cardiac chamber filling pressures (cardiogenic pulmonary edema).
Despite our sophisticated knowledge of heart failure, even
so-called ejection fraction-preserved heart failure has high
rates or mortality and morbidity. So, novel therapies are sorely
needed. With over a million hospitalizations annually–up
175% over the past 25 years–and costs of nearly $15.4 billion
dollars, acute heart failure is a critically-important health concern. Furthermore, half of patients discharged from the hospital are readmitted within half-a-year. In-hospital mortality
remains high between 4–7%.1,2 Heart failure is a significant

Systematic reviews
Observational studies
Commentary on clinical trials
Risk and safety of medical interventions
Epidemiology and statistical methods
Evidence-based medicine
Evaluation of guidelines
Translational medicine
Article types include original clinical and basic research
articles, case reports, commentaries, meeting reports, methodology, perspective, research proposal, reviews, software/
database reviews, and technical advance.

problem as the population ages. The prevalence is 2.5% of
the U.S. population or 5 million patients (from the National
Health and Nutrition Education Survey: NHANES).2
Common etiological mechanisms of heart failure include
coronary ischemia, valvular disease, hypertension, and diastolic dysfunction. Yet, other causes include: post-partum cardiomyopathy, post-infectious, chronic tachycardia, metabolic
dysregulation, adverse medication side effects (particularly
adriamycin chemotherapy), orphan disease Duchenne’s Muscular Dystrophy, infiltrative diseases (such as amyloidosis),
and inflammatory/connective tissue diseases (such as systemic
lupus erythematosus). When known causes of heart failure are
excluded then heart failure is classified as idiopathic. Less often
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studied versus chronic heart failure, is acute decompensated
heart failure associated with abrupt-onset symptoms associated with hospitalization. Nearly half of admitted patients with
heart failure have preserved ejection fraction.2,3
Survival among heart failure patients long-term may be
improved with β-blockers,4 angiotensin converting enzyme
inhibitors,5 aldosterone antagonists,6 electrophysiology devices
such as automatic implantable cardiovascular defibrillators,
and vasodilators. Other drugs such as digoxin and diuretics do
not alter death rates–digoxin reduces hospitalizations, while
diuretics (furosemide or lasix) improve symptoms.
Another aspect of heart failure is diastolic dysfunction
with preserved left ventricular ejection fraction, accounting for
half of hospitalizations. Pathophysiologically, there is concentric
remodeling and increased left ventricular end diastolic pressure
from a stiff left ventricle, thereby preventing relaxation. Medications for diastolic dysfunction are similar to systolic dysfunction: ACE inhibitors, ARBs, diuretics, and β-blockers.7
Left ventricular assist devices (LVADs) as both a bridge
to heart transplantation or as a destination unto itself have
been developed. Limitations to LVADs entail gastrointestinal
bleeding, pump thrombosis, driveline infection, and late right
heart failure and aortic insufficiency. Cardiac transplantations
are limited by a relatively small annual donor pool (4000)8
and 60% five-year survival.9
Notable manuscripts in this supplement to Clinical Medicine Insights: Cardiology “Heart Failure: An Exploration of
Recent Advances in Research and Treatment (A)” review viable
options for end-stage heart failure. Dr. Allison McLarty discusses mechanical circulatory support and the role of LVADs
in Heart Failure Therapy. Dr. McLarty presents a practical
review and guideline for LVAD use.8 Dr. Fahad Gilani et al.
discuss “Percutaneous Mechanical Support in Cardiogenic
Shock: A Review” and note that mortality is not improved
with Intra-Aortic Balloon Pumps (IABP), Extracorporeal
Membrane Oxygenation (ECMO) or percutaneous LVADs.10
Dr. David Bejar and colleagues review sundry abnormal substances which may infiltrate the heart to lead to
“Infiltrative Cardiomyopathies” as a prelude to heart failure.
While Fabry Disease necessitates enzyme replacement with
α-galactosidase A, other diseases like hemochromatosis warrant phlebotomy and deferoxamine, and AL cardiac amyloid
may respond to bortezomib, yet other etiologic mechanisms
are incurable, leading to heart transplantation.11
An overlooked topic relates to geriatrics, so in regard to
heart failure, Drs. Deena Goldwater and Sean Pinney bring
up for discussion “ Frailty in Advanced Heart Failure: A Consequence of Aging or a Separate Entity?” With the prevalence
of frailty higher at 20% of the heart failure population versus
10% in a matched aged cohort, the molecular mechanisms
underpinning these differences warrant investigation.12
As a complementary article to the mechanical support
reviews noted supra vide, Dr. Harsh Patel offers recommendations on monitoring for “Complications of Continuous-Flow
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Mechanical Circulatory Support Devices” with echocardio
graphy and judicious use of inotrotropic agents and antibiotics.
Dr. Patel points out that AICDs pre-LVAD are kept for their
improvement in mortality, however, mortality worsens with
AICD shocks.13
Finally, I would like to comment on “Reversible Cardio
myopathies” by Dr. Harsh Patel and co-authors, which
reminds us to search the treatable, such as Sympathoexcitation-Induced Takotsubo Cardiomyopathy due to excess
catecholamines from autonomic dysfunction. Despite spontaneous reversibility aided with beta-blockers and angiotensin
converting enzyme inhibitors, heart recidivism rates are 11.4%
at 4 years.14
We are fortunate to be practicing at an exciting time for
the profession of medicine–an era of rapid evolution in technology and knowledge-base in basic science. What this may
hold for the short-term treatment of heart failure remains to
be seen, but ultimately the goal will be to help us improve
upon current practice. Bioinformatics, computational biology, genomics, proteomics, metabolomics, pharmacology, and
quantitative epidemiology may be part-and-parcel of the next
issue of “Heart Failure: An Exploration of Recent Advances
in Research and Treatment.”
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